Personalized approach to the selection of therapy for patients with psoriasisbased on the results of molecular and genetic tests
- Authors: Znamenskaya LF1, Frigo NV1, Rotanov SV1, Volkov IA1, Volnukhin VA1, Zhilova MB2
-
Affiliations:
- ФГУ «ГНЦД Росмедтехнологий», г. Москва
- «ГНЦД Росмедтехнологий», г. Москва
- Issue: Vol 86, No 5 (2010)
- Pages: 77-83
- Section: Articles
- URL: https://journals.rcsi.science/0042-4609/article/view/117351
- DOI: https://doi.org/10.25208/vdv961
- ID: 117351
Cite item
Full Text
Abstract
and phototherapy with the use of molecular and genetic technologies. The authors revealed that the predictor of evident clinical
response to treatment of psoriasis patients with Infliximab is the homozygous TT genotype at the 676 locus of exon 6 of the TNFR-
II gene; predictors of high efficacy and safety of treatment of psoriasis patients with Infliximab with the use of ultraviolet therapy
(PUVA and mid-wavelength ultraviolet therapy (311 nm)) are: heterozygous GA genotype at the 19007 locus of the ERCC gene
and homozygous CC genotype at the 27945 locus of the XPF gene.
About the authors
L F Znamenskaya
ФГУ «ГНЦД Росмедтехнологий», г. Москва
Email: znaml@cnikvi.ru
к.м.н.; ФГУ «ГНЦД Росмедтехнологий», г. Москва
N V Frigo
ФГУ «ГНЦД Росмедтехнологий», г. Москвад.м.н.; ФГУ «ГНЦД Росмедтехнологий», г. Москва
S V Rotanov
ФГУ «ГНЦД Росмедтехнологий», г. Москвад.м.н.; ФГУ «ГНЦД Росмедтехнологий», г. Москва
I A Volkov
ФГУ «ГНЦД Росмедтехнологий», г. Москвак.б.н.; ФГУ «ГНЦД Росмедтехнологий», г. Москва
V A Volnukhin
ФГУ «ГНЦД Росмедтехнологий», г. Москвад.м.н.; ФГУ «ГНЦД Росмедтехнологий», г. Москва
M B Zhilova
«ГНЦД Росмедтехнологий», г. Москвак.м.н.; «ГНЦД Росмедтехнологий», г. Москва
References
- Jariwala S.P. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res 2007 Oct; 299(8): 359-66.
- Mahlknecht U., Voelter-Mahlknecht S. Pharmacogenomics: questions and concerns. Curr Med Res Opin 2005; 21(7): 1041-1047.
- Global Technology Center, Health Research Institute. Personalized Medicine. The Emerging Pharmacogenomics Revolution. Pricewaterhouse Coopers, February, 2005.
- Sadee W. Pharmacogenomics. BMJ 1999; 319: 1286.
- Mascheretti S., Hampe J., Kuhbacher T. et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002; 2 (2): 127-136.
- Matsukura H., Ikeda S., Yoshimura N. et al. Genetic polymorphisms of TNF receptor superfamily 1A and 1B (TNFRSF1A and TNFRSF1B) affect responses to infliximab in Crohn's disease patients in Japan. Aloment Pharmacol Ther 2008, Jan 28.
Supplementary files
